Aldeyra Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $40.12M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2023 Ended Mar 31, 2023 | May 4, 2023 | Before market open | – | $-0.27 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 9, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 10, 2022 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 5, 2022 | Before market open | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 5, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 17, 2022 | Before market open | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Oct 28, 2021 | Before market open | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 5, 2021 | Before market open | – | – | – |
| Q1 FY2021 Ended Mar 31, 2021 | May 6, 2021 | Before market open | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Mar 11, 2021 | Before market open | – | – | – |
| Q3 FY2020 Ended Sep 30, 2020 | Nov 5, 2020 | Before market open | – | – | – |
| Q2 FY2020 Ended Jun 30, 2020 | Aug 6, 2020 | Before market open | – | – | – |
Press releases
Announcements Aldeyra Therapeutics filed with the SEC
Reproxalap for the Potential Treatment of Dry Eye Disease: Regulatory Update CONFERENCE CALL September 29, 2026 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2026 Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Innovative Therapeutics for Immune-Mediated Diseases CORPORATE OVERVIEW May 2026 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2026 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
2025 Research & Development Webcast CORPORATE OVERVIEW November 13, 2025 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2025 Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED JULY 17, 2025
Other events · EX-99.1 to Form 8-K
ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED JUNE 26, 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED JUNE 17, 2025
Other events · EX-99.1 to Form 8-K
Topline Data Release and NDA
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Treatment of Dry Eye Disease: Regulatory Update April 3, 2025 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED NOVEMBER 18, 2024
Material agreement · Other events · EX-99.1 to Form 8-K
ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED OCTOBER 3, 2024
Other events · EX-99.1 to Form 8-K
ALDEYRA THERAPEUTICS, INC. PRESENTATION DATED AUGUST 8, 2024
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED AUGUST 8, 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED JUNE 20, 2024
Other events · EX-99.1 to Form 8-K
ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED JUNE 13, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
SLIDE PRESENTATION OF ALDEYRA THERAPEUTICS, INC. DATED APRIL 25, 2024.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE OF ALDEYRA THERAPEUTICS, INC. DATED APRIL 25, 2024.
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED MARCH 28, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Innovative Therapeuticsfor Immune-Mediated Diseases CORPORATE OVERVIEW February
Regulation FD disclosure · EX-99.1 to Form 8-K
Top-Line Results from thePhase 2 Clinical Trial of ADX-629in Atopic
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Dry Eye Disease Regulatory Update November 28, 2023 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2023
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Top-Line Results from thePhase 2 Clinical Trial of ADX-2191 in Retinitis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Top-Line Results from thePhase 2 Clinical Trial ofADX-629 in Chronic Cough DATA
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Aldeyra Therapeutics Provides Regulatory Update on ADX-2191
Other events · EX-99.1 to Form 8-K
Top-Line Results from thePhase 3 INVIGORATE-2 Trial in Allergic Conjunctivitis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
Results of operations · Other events · EX-99.1 to Form 8-K